Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older.
- Have an IDH1 mutation in tumor testing—specifically the R132 change (other IDH1 changes like R100 may qualify after review).
- Have AML after relapse/refractory treatment, or high-risk MDS/MDS-MPN/MPN (often after standard treatments).
- Have enough liver and kidney function on blood tests (unless doctors think it’s caused by leukemia).
- Be healthy enough to take part (performance status below 2) and be able to sign informed consent.
- Have not taken ivosidenib or venetoclax before, and be free from known drug allergy to them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.